BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17314336)

  • 1. DNA repair and survival in lung cancer--the two faces of Janus.
    Gazdar AF
    N Engl J Med; 2007 Feb; 356(8):771-3. PubMed ID: 17314336
    [No Abstract]   [Full Text] [Related]  

  • 2. ERCC1 and non-small-cell lung cancer.
    Panasci L; Cohen V
    N Engl J Med; 2007 Jun; 356(24):2540; author reply 2540-1. PubMed ID: 17575589
    [No Abstract]   [Full Text] [Related]  

  • 3. ERCC1 measurements in clinical oncology.
    Reed E
    N Engl J Med; 2006 Sep; 355(10):1054-5. PubMed ID: 16957152
    [No Abstract]   [Full Text] [Related]  

  • 4. ERCC1 and non-small-cell lung cancer.
    Zhou SF
    N Engl J Med; 2007 Jun; 356(24):2540; author reply 2540-1. PubMed ID: 17575590
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical significance of ERCC1, RRM1 and TS in non-small cell lung cancer].
    Li P; Kang X; Chen K
    Zhongguo Fei Ai Za Zhi; 2014 Jun; 17(6):496-500. PubMed ID: 24949692
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
    Hamilton G; Rath B
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):17-24. PubMed ID: 29226731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA repair by ERCC1 in non-small-cell lung cancer.
    Cecere F; Bria E; Rosell R
    N Engl J Med; 2006 Dec; 355(24):2590-1; author reply 2591. PubMed ID: 17167144
    [No Abstract]   [Full Text] [Related]  

  • 8. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.
    Zheng Z; Chen T; Li X; Haura E; Sharma A; Bepler G
    N Engl J Med; 2007 Feb; 356(8):800-8. PubMed ID: 17314339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA repair by ERCC1 in non-small-cell lung cancer.
    Grenader T; Shavit L
    N Engl J Med; 2006 Dec; 355(24):2591; author reply 2591. PubMed ID: 17167936
    [No Abstract]   [Full Text] [Related]  

  • 10. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer.
    Okuda K; Sasaki H; Hikosaka Y; Kawano O; Yukiue H; Yano M; Fujii Y
    J Surg Res; 2011 Jun; 168(2):206-12. PubMed ID: 20070981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair by ERCC1 in non-small-cell lung cancer.
    Wilcox JE
    N Engl J Med; 2006 Dec; 355(24):2590; author reply 2591. PubMed ID: 17171818
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of genomics in NSCLC.
    Rosell R; Cobo M; Isla D; Sanchez JM; Taron M; Altavilla G; Santarpia M; Moran T; Catot S; Etxaniz O
    Lung Cancer; 2005 Dec; 50 Suppl 2():S33-40. PubMed ID: 16557672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer.
    KimCurran V; Zhou C; Schmid-Bindert G; Shengxiang R; Zhou S; Zhang L; Zhang J
    Adv Med Sci; 2011; 56(1):30-8. PubMed ID: 21536539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720.
    Bepler G
    Clin Lung Cancer; 2007 Sep; 8(8):509-11. PubMed ID: 17948610
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacogenomics: a reality or still a promise?
    Bepler G
    Lung Cancer; 2006 Dec; 54 Suppl 2(Suppl 2):S3-7. PubMed ID: 17064812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC.
    Vilmar A; Garcia-Foncillas J; Huarriz M; Santoni-Rugiu E; Sorensen JB
    Lung Cancer; 2012 Mar; 75(3):306-12. PubMed ID: 21996087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.